Novo Nordisk A/S Presents FDA New Data Confirming No Link between Victoza and Cancer-Reuters


Friday, 14 Jun 2013 01:00am EDT 

Reuters reported that Novo Nordisk A/S is to present to U.S. Food and Drug Administration (FDA) new data confirming that the Company's GLP-1-analogue, Victoza, cannot be linked to cancer. The action has been taken to deny any suggestions that Victoza can lead to pancreatic cancer. 

Company Quote

235.6
4.9 +2.12%
16 Apr 2014